Pulmonx Reports Second Quarter 2026 Financial Results
Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmonx Reports Second Quarter 2026 Financial Results Redwood City, CA - July 29, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the secon
How this was made
The 30-second read
Why it matters
Traders can update models using the explicit FY2026 revenue range ($90M-$92M), gross margin target (~76%), and operating expense range ($109M-$111M). The China registration renewal wait is a specific near-term swing factor for international revenue and could drive revisions if timing changes.
Market read
Fresh earnings and guidance numbers for a small-cap healthcare name, with margin improvement and cost realignment partially offset by continued YoY revenue declines and China-related sales disruption.
What to watch
The guidance assumes no additional drawdowns under the credit facility; changes in financing needs or timing of China registration renewal could shift the revenue and cash trajectory faster than the ranges imply.
Background
This SEC 8-K includes Pulmonx’s Q2 2026 results (ended June 30, 2026) and updated full-year 2026 financial outlook, plus a note that international revenue declined due to lack of sales into China while a registration certificate is renewed.
Ticker impact
Pulmonx reported Q2 2026 revenue of $22.8M (down 5% YoY) and updated FY2026 guidance to $90M-$92M revenue and ~76% gross margin.
Near-term volatility likely around the updated FY revenue range and gross margin outlook, with traders focusing on whether operating leverage can offset the YoY revenue decline.
The filing provides fresh, company-specific datapoints: Q2 results, record 78% gross margin, reduced net loss/adjusted EBITDA loss, and explicit FY2026 revenue, gross margin, and operating expense ranges. The China registration renewal wait is also a concrete driver of international revenue variability.
Market effects
Adds a datapoint on commercial execution and cost realignment for a minimally invasive lung-disease treatment company, relevant to small-cap medtech sentiment.
Limited direct regional read-through beyond US-listed small-cap healthcare risk appetite.
International revenue weakness tied to China registration highlights regulatory/market-access sensitivity for global medtech revenue streams.
Counterpoint
Record gross margin may not translate into sustained revenue growth if China access remains constrained and US/international demand continues to soften.
Key entities
- companyPulmonx Corporation
Nasdaq-listed company reporting Q2 2026 financial results and updating FY2026 guidance in an SEC 8-K.
- executiveGlen French
CEO who commented on commercial strategy execution, clinical initiatives, and expected operating leverage.
